BioRestorative Therapies Announces Closing of $23 Million Public Offering

About this update from Biorestorative Therapies, Inc.

[{"type":"text","content":"MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company\") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00. The warrants have a per share exercise price of $10.00, are exercisable immediately, and expire five years from the date of issuance. In addition, the underwriter has partially exercised its option to purchase additional securities by purchasing warrants to purchase up to 345,000 shares of common stock. The aggregate gross proceeds from the offering are approximately $23 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with the offering, on November 5, 2021, the Company’s common stock was listed on the Nasdaq Capital Market under the ticker symbol “BRTX”. Roth Capital Partners acted as sole manager for the offering. The securities described above were sold by BioRestorative Therapies pursuant to a registration statement on Form S-1 (Registration No. 333-258611) that was previously filed by BioRestorative Therapies with the Securities and Exchange Commission (the “SEC”) and declared effective on November 4, 2021 and an additional registration statement filed pursuant to Rule 462(b), which became effective upon filing. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering was made only by means of the written prospectus forming part of the effective registration statement. Electronic copies of the accompanying prospectus may be obtained by contacting Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, Attn: Prospectus Department, telephone: 800-678-9147, or email at [email protected], or by visiting the SEC’s website at http://www.sec.gov. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. (www.biorestorative.com) ...

More updates from Biorestorative Therapies, Inc.